Announcements Trials
Browse Landscape

Status

Approved for marketing 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 177Observational 7Expanded_access 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Head and Neck Neoplasms 1

Interventions

Afatinib 3ceritinib 2Gefitinib 2zipalertinib 1zenocutuzumab 1ulixertinib 1trilaciclib 1telisotuzumab vedotin 1tazemetostat 1taletrectinib 1sotorasib 1selpercatinib 1rovalpituzumab tesirine 1rociletinib 1pralsetinib 1pegilodecakin 1patritumab deruxtecan 1osimertinib 1mobocertinib 1lorlatinib 1lazertinib 1epigallocatechin gallate 1ensartinib 1dabrafenib 1cemiplimab 1capmatinib 1brigatinib 1belagenpumatucel L 1balstilimab 1amivantamab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × Gefitinib × Thoracic × Clear all
NCT00684385 2019-03-14

An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck

AstraZeneca

Approved for marketing
Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms

NCT00683306 2018-09-13

Open Label Extension Study With Gefitinib (IRESSAâ„¢) for Completing Trial Patients Who May Benefit From Further Treatment

AstraZeneca

Approved for marketing
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡